Significant appointments of experienced drug development and financial experts – Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut Versameb AG (“Versameb”), transforming (m)RNA therapeutics to cure hard-to-treat and/or prevalent diseases, is pleased to announce the appointments of Hernán Levett, Dr Lily Geidelberg, Paul Korner, MD, MBA and Dr Alexandre LeBeaut to its […]
Professor Dmochowski is a world leading key opinion leader in female urology and urologic reconstruction Versameb is accelerating preparations for IND filing of lead candidate VMB-100 Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, is pleased to announce the appointment of Professor Roger Dmochowski as Chief Medical Officer […]
Versameb AG (“Versameb”), a pre-clinical stage company focused on discovering and developing innovative RNA-based therapeutics, today announces that its Chief Executive Officer, Klaas Zuideveld will be presenting on the Company’s mRNA engineering technology platform VERSagile and lead therapeutic candidate VMB-100 at the BIO Asia-Taiwan Conference, taking place on 27-31 July 2022 in Taiwan. Read more…
Optimum Strategic Communications is pleased to support Versameb during World Continence Week, a company raising awareness of the high unmet medical need of patients suffering with Stress Urinary Incontinence (SUI) and continence related issues which impacts the lives of millions of patients worldwide. Versameb’s Chief Executive Officer, Klaas Zuideveld to present on the Company’s proprietary […]
Lead therapeutic candidate has the potential to treat Stress Urinary Incontinence Raising awareness of the high unmet medical need of patients Versameb AG (“Versameb”), focused on discovering and developing innovative RNA-based drugs, is pleased to announce that Chief Executive Officer Klaas Zuideveld and Clinical Advisor Prof. Roger Dmochowski will be presenting Versameb’s lead therapeutic candidate, […]
